Related posts

Stocks sink for the day and weekMoody’s downgrade pressures stocksTSX and Dow gain for the week
Investor Insights

This summary was created by AI, based on 15 opinions in the last 12 months.

Experts have mixed opinions about Zoetis Inc (ZTS) with some believing in its strong market position and growth potential, especially in the pet division, while others are cautious due to concerns about competition and the controversial dog arthritis drug, Librela. The company's high valuation and decline in share price due to competition are also noted, but overall, the stock is seen as resilient and offering an attractive long-term opportunity.

Consensus
Mixed
Valuation
Fair Value
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Zoetis Inc
(A Top Pick Mar 14/24, Up 4.6%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with ZTS has triggered its stop at $181.  To remain disciplined, we recommend covering the position at this time.  

Consumer Products
HOLD
Zoetis Inc
Controversial dog arthritis drug.

Librela's actually been on the market for a while, launched in Europe before US. Debate whether it helps or does it cause adverse effects. Company still tags very strong growth for this drug, vets are still recommending it. Reports in a week or two, so we'll get more visibility. If growth stalls on this one, a negative for the stock. So far, things seem on track.

Librela is important, as company thinks it can be a blockbuster. Their other drugs are doing quite well, pipeline is healthy.

Consumer Products
DON'T BUY
Zoetis Inc

Companion pets are a big thing. Growing need for protein from livestock. Above 200-day MA, but that's moving sideways. Trendlines are not fantastic. Trading at 31x, with 10% growth rate, PEG of 3, a bit expensive.

Consumer Products
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Zoetis Inc
(A Top Pick Mar 14/24, Up 11%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with ZTS is progressing well.  To be disciplined, we recommend trailing up the stop (from $161) to $181 at this time.  

Consumer Products
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Zoetis Inc
(A Top Pick Mar 14/24, Up 5.2%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with ZTS is progressing well.  To remain disciplined, we recommend trailing up the stop (from $140) to $161 at this time.  

Consumer Products
BUY
Zoetis Inc

Likes the industry in general. A leader. Vets like its products. Not a lot of generic competition. Diversified in types of care. Studies show that pet spending is resilient even during slowdowns. Attractive entry point.

Consumer Products
DON'T BUY
Zoetis Inc

Shares are declining because they now face competition. It's no longer a one-horse race.

Consumer Products
PAST TOP PICK
Zoetis Inc
(A Top Pick Jun 13/23, Up 6%)

A bit disappointing. Headwind from near-term, cyclical pressures as economy weakens and vet visits decline. Company sees itself as defensive -- people prioritize their pets, aging population, younger generation having pets instead of children. Competition on drugs, adverse press to dog pain management drug. Still likes longer, secular trend.

Consumer Products
TOP PICK
Zoetis Inc

2/3 pet pharma, 1/3 livestock. Time to market is lower than for human pharma, not as much generic competition. Overhang from negative press about unwanted effects from painkillers -- anecdotal, not based on data. Good growth going forward. Yield is 1%.

(Analysts’ price target is $206.40)
Consumer Products
BUY
Zoetis Inc

Livestock has come back since Covid plus, as people become wealthier, they eat more protein. Pet side is going like gangbusters. Lots of products in pipeline. Incredible run during Covid, now taking a break. Will continue to do well.

Consumer Products
TOP PICK
Zoetis Inc

Pet division is about 2/3 of revenue, livestock makes up the rest. Around for 65 years, spun off from PFE 10 years ago. Animal health industry has very little generic competition, so product life tends to be over 25 years. Leading share globally. Invests in R&D. Pullback is attractive opportunity. Yield is 1%.

(Analysts’ price target is $217.14)
Consumer Products
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Zoetis Inc
Stockchase Research Editor: Michael O’Reilly

We select ZTS, the manufacturer of livestock and companion animal pharmaceuticals as a TOP PICK.  Quarterly cash flow is growing, while shares are bought back.  It has a strong market position, confirmed by its 49% ROE.  Its modest dividend is supported by a payout ratio of 30% of cash flow.  Animal care is a certain and growing sector.  We recommend setting a stop-loss at $140, looking to achieve $226 — upside potential of 29%.  Yield 0.9%

(Analysts’ price target is $225.85)
Consumer Products
BUY
Zoetis Inc
Net income to free cashflow conversion went down.

That conversion metric is a good one. Transitioning some drugs, so growth has slowed, impacting free cashflow. Increase in R&D taking up capital. New drugs in pipeline. Story still stands. Good value compounder over time.

Consumer Products
WEAK BUY
Zoetis Inc

Their last quarter was weak, but he thinks it's a one-off event. Be believes in the CEO and company long term.

Consumer Products
BUY ON WEAKNESS
Zoetis Inc

Stock's done well, especially with recent rally. For new money, wait for pullback, and we'll get that eventually. Great products, especially launch of drug for canine arthritic pain. Pet division is somewhat recession-resistant.

Consumer Products
Showing 1 to 15 of 92 entries

Zoetis Inc(ZTS-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 9

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 12

Stockchase rating for Zoetis Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Zoetis Inc(ZTS-N) Frequently Asked Questions

What is Zoetis Inc stock symbol?

Zoetis Inc is a American stock, trading under the symbol ZTS-N on the New York Stock Exchange (ZTS). It is usually referred to as NYSE:ZTS or ZTS-N

Is Zoetis Inc a buy or a sell?

In the last year, 12 stock analysts published opinions about ZTS-N. 9 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Zoetis Inc.

Is Zoetis Inc a good investment or a top pick?

Zoetis Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Zoetis Inc.

Why is Zoetis Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Zoetis Inc worth watching?

12 stock analysts on Stockchase covered Zoetis Inc In the last year. It is a trending stock that is worth watching.

What is Zoetis Inc stock price?

On 2024-12-11, Zoetis Inc (ZTS-N) stock closed at a price of $177.17.